A Look At Payers' Early Game Plans For Driving Biosimilar Use
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
You may also be interested in...
Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018
Sandoz needs to do another study to satisfy FDA, while Amgen says it faces a slow pace of patent litigation with AbbVie.
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.
Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence
New PBM management program aims to cut in half the projected increases in diabetes drug spending in 2017, improve patient adherence rates by 5%.